A Vibrant Life Sciences Community
Campus Biotech Innovation Park now hosts 23 startups, 7 foundations, 3 VCs, 13 support organisations, as well as UNIGE, EPFL Extension School and Geneva Tsinghua Initiative in the SDG solution space.
CBIP startups are thriving:
This summer, iOnctura SA, a clinical-stage biopharmaceutical company developing a pipeline of next-generation molecules targeting cancer and fibrosis, raised an additional EUR 5.1 million bringing its total Series A financing to EUR 20.1 million. Read more here.
Relief Therapeutics started clinical trial in patients with Covid-19. The findings of Dr. Youssef and his team demonstrate that some critically ill patients with COVID-19 experienced substantial clinical improvement when treated with RLF-100. Read about this news here.
ID-Gene are another example of how startups adapt to meet the new needs. ID-Gene offer fast, sensitive and reliable environmental DNA tests. They are now redirecting a part of their activity to the detection of the SARS coronavirus 2 in wastewaters (SARS coronavirus 2 being the strain of coronavirus that causes COVID-19). Recent studies showed that the quantity of virus in wastewaters arriving at water treatment plant seemed to be correlated with the number of infection cases reported in the region.
Esperare are a not-for-profit organisation who uncover the potential of existing therapies to address severe unmet therapeutic needs in rare diseases. In their latest news, they announced that the U.S. FDA has granted Breakthrough Therapy Designation for the prenatal treatment of XLHED, a life-threatening, rare genetic condition which prevents babies from being able to sweat. We congratulate Esperare for their wonderful work and this great achievement.
ABCDx founders, Prof. Sanchez and Dr. Montaner are published in Nature Reviews Neurology. In this article, the authors discuss the current status of biomarker research in stroke towards clinical stroke management. The two Key Opinion Leaders bring together over 45 years of experience, 562 publications and 39 patents.
CHORD Therapeutics, a clinical stage bio-pharmaceutical company based at Campus Biotech Innovation Park, developing drugs for rare diseases, announced on October 13 the closing of a USD16 million Series A financing exclusively from leading healthcare investor Omega Funds. In conjunction with the financing, Omega Funds’ Managing Director Claudio Nessi and Principal Francesco Draetta will join the Board. Read the full press release here.
One of our missions is to provide a home for Geneva’s vibrant life sciences innovation community.
Over the past year we have welcomed 900 attendees to over 25 events that we have proudly virtually or physically co-hosted with partners including Open Geneva, UNIGE, and the Geneva Tsingua Initiative.
Each month 60 life sciences professionals join us physically and virtually for our monthly Café & Croissant. CBIP also hosts the business concept course of Innosuisse, with 30 researchers and students learning how to tackle the challenges of launching a startup company.
Serial entrepreneur Michel Jordi during the Geneus Open Day
If you want to stay up to date with developments in life sciences, we can warmly recommend Campus Biotech’s monthly feeds. Click here to sign up.
Our digital community has grown to include over 3500 life sciences innovation enthusiasts who follow our Facebook and LinkedIn page.